Lyell Immunopharma (LYEL) Enterprise Value (2019 - 2025)
Lyell Immunopharma (LYEL) has disclosed Enterprise Value for 7 consecutive years, with -$247.2 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 33.28% to -$247.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$247.2 million through Dec 2025, up 33.28% year-over-year, with the annual reading at -$247.2 million for FY2025, 33.28% up from the prior year.
- Enterprise Value hit -$247.2 million in Q4 2025 for Lyell Immunopharma, up from -$319.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$244.4 million in Q1 2021 to a low of -$824.5 million in Q2 2021.
- Historically, Enterprise Value has averaged -$508.2 million across 5 years, with a median of -$560.8 million in 2023.
- Biggest five-year swings in Enterprise Value: crashed 360.46% in 2021 and later soared 43.64% in 2025.
- Year by year, Enterprise Value stood at -$614.8 million in 2021, then decreased by 4.12% to -$640.2 million in 2022, then grew by 14.67% to -$546.2 million in 2023, then soared by 32.17% to -$370.5 million in 2024, then surged by 33.28% to -$247.2 million in 2025.
- Business Quant data shows Enterprise Value for LYEL at -$247.2 million in Q4 2025, -$319.6 million in Q3 2025, and -$276.8 million in Q2 2025.